Tocilizumab is marketed as ACTEMRA, an interleukin-6 receptor inhibitor used across rheumatologic diseases, cytokine release syndrome, and hospitalized COVID-19 in defined age groups and severity settings. It is available for intravenous or subcutaneous administration depending on indication. U.S. initial approval was in 2010.
CAR-T toxicity management is shifting toward phenotype- and mechanism-based intervention. Key issues include CRS, ICANS, IEC-HS, and long-term risks of cytopenia and infection.
New research demonstrates that dexamethasone effectively ameliorates cytokine-release syndrome in CAR T-cell therapy for multiple myeloma while maintaining or enhancing anti-tumor activity and increasing CAR T-cell levels.
T-cell immunotherapies including CAR T-cell therapy and T-cell engagers are expanding cancer treatment options but present significant cardiovascular risks and operational complexities requiring coordinated multidisciplinary management.
New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.
The European Commission has approved Gotenfia (golimumab), a biosimilar to Simponi developed by Bio-Thera and marketed by STADA, for chronic inflammatory autoimmune diseases across the EU and EEA.
The European Commission has granted marketing authorization for Gotenfia, a golimumab biosimilar to Simponi, developed by Bio-Thera and to be commercialized by STADA across the EU, EEA, UK, Switzerland and selected other countries.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774247 |
Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07709000 |
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07708038 |
Anti-Interleukin-6 (IL6) in Calciphylaxis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07643038 |
Treatment Strategy for Patients With RA-ILD |
NOT_YET_RECRUITING | PHASE4 |
| NCT07637578 |
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma |
RECRUITING | PHASE2 |
| NCT07629583 |
To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis |
RECRUITING | PHASE1 |
| NCT07609940 |
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) |
RECRUITING | PHASE4 |
| NCT07595900 |
Tocilizumab for the Treatment of Refractory Granulomatous Lobular Mastitis |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07594067 |
TCR1188-ABC Cells in KRAS-mutated Cancers |
RECRUITING | PHASE1 |
| NCT07589634 |
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma |
RECRUITING | PHASE2 |
